155 related articles for article (PubMed ID: 38401247)
1. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Rao S; Anandappa G; Capdevila J; Dahan L; Evesque L; Kim S; Saunders MP; Gilbert DC; Jensen LH; Samalin E; Spindler KL; Tamberi S; Demols A; Guren MG; Arnold D; Fakih M; Kayyal T; Cornfeld M; Tian C; Catlett M; Smith M; Spano JP
ESMO Open; 2022 Aug; 7(4):100529. PubMed ID: 35816951
[TBL] [Abstract][Full Text] [Related]
4. POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma.
Rao S; Jones M; Bowman J; Tian C; Spano JP
Front Oncol; 2022; 12():935383. PubMed ID: 36091159
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
Berton D; Pautier P; Lorusso D; Gennigens C; Gladieff L; Kryzhanivska A; Bowman J; Tian C; Cornfeld M; Van Gorp T
Gynecol Oncol; 2024 Jun; 186():191-198. PubMed ID: 38824752
[TBL] [Abstract][Full Text] [Related]
6. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
7. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
8. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
Galffy G; Lugowska I; Poddubskaya EV; Cho BC; Ahn MJ; Han JY; Su WC; Hauke RJ; Dyar SH; Lee DH; Serwatowski P; Estelles DL; Holden VR; Kim YJ; Vladimirov V; Horvath Z; Ghose A; Goldman A; di Pietro A; Wang J; Murphy DA; Alhadab A; Laskov M
ESMO Open; 2023 Jun; 8(3):101173. PubMed ID: 37141847
[TBL] [Abstract][Full Text] [Related]
9. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y; Chen G; Chen J; Zhuang L; Du Y; Yu Q; Zhuang W; Zhao Y; Zhou M; Zhang W; Zhang Y; Wan Y; Li W; Song W; Wang ZM; Li B; Xia M; Yang Y; Fang W; Huang Y; Zhang L
EClinicalMedicine; 2023 Aug; 62():102106. PubMed ID: 37593227
[TBL] [Abstract][Full Text] [Related]
10. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
12. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
13. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
[TBL] [Abstract][Full Text] [Related]
14. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
[TBL] [Abstract][Full Text] [Related]
17. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
19. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
[TBL] [Abstract][Full Text] [Related]
20. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
